# Assembly Biosciences, Inc. (ASMB)

> Source: Nexqual · https://nexqual.com/ASMB · data as of 2026-11-17 21:00 UTC · cite as "Nexqual, Assembly Biosciences, Inc. (ASMB), nexqual.com/ASMB" · informational, not investment advice.

## What changed for ASMB since Aug 31, 2025
The built-in knowledge of several widely used AI models ends around Aug 31, 2025. Everything below is newer, dated and sourced (as of Nov 17, 2026).

- Assembly Biosciences, Inc. (ASMB) stock went from USD 24.7 (close of the week of Aug 25, 2025, split-adjusted) to USD 22.5, a -8.9% price change; the S&P 500 (SPY) moved +15.1% over the same period.
- ASMB revenue over the last four reported quarters (through Sep 30, 2026) was $67.0M, +135.0% vs $28.5M in fiscal year 2024 (ended Dec 31, 2024), the last full year filed before September 2025; net income -$40.2M → -$11.1M (SEC 10-K / 10-Q).
- Analyst actions on ASMB in the last 120 days: 4 (0 upgrades or target raises, 2 downgrades or target cuts); most recent UBS, Nov 3, 2026.

**Price:** USD 22.5 (+5.68% on the day) · last close of Nov 17, 2026; US market open, not a live price. Prev close 21.29 · day 21.15–22.6 · 52w 19.2–39.71 · market cap $461M · NMS

## Key facts
- Last four reported quarters (through Sep 30, 2026): revenue $67.0M, net income -$11.1M (-16.6% margin), free cash flow -$40.7M (SEC filings).
- Analysts: Buy (mean 2.00 on a 1–5 scale) (5 analysts), mean target USD 51.2 (range 43–62).
- Total return with dividends: 1Y -37.3% vs S&P 500 +12.2%; 5Y -18.5% vs S&P 500 +67.0%.
- Dividend: ASMB paid no cash dividend in the last five years.
- Short interest: 19.82% of float (as of 2026-10-30), 13.6 days to cover.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $6.3M | $0K | $7.2M | $28.5M | $72.3M | $67.0M |
| Operating income | -$133M | -$94.1M | -$64.6M | -$45.4M | -$12.1M | -$21.3M |
| Net income | -$130M | -$93.1M | -$61.2M | -$40.2M | -$6.1M | -$11.1M |
| EPS (diluted) | -$36.00 | -$23.08 | -$13.38 | -$6.69 | -$0.55 | — |
| Free cash flow | -$96.5M | -$84.6M | $22.5M | -$51.1M | -$41.2M | -$40.7M |
| Operating margin | -2121.7% | — | -902.5% | -159.3% | -16.8% | -31.8% |
| Net margin | -2076.4% | — | -854.8% | -140.9% | -8.5% | -16.6% |
| Revenue growth | -92.1% | -100.0% | — | +298.2% | +153.5% | — |
| Cash + short-term investments | $147M | $91.6M | $130M | $112M | $248M | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Sep 30, 2026)
P/S 6.9x · P/B 1.5x · FCF yield -8.83% · Earnings yield -2.41%

## Analysts
Consensus Buy (mean 2.00 on a 1–5 scale), 5 analysts; mean target USD 51.2 (low 43, high 62).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-11-03 | UBS | Target lowered | Buy | $52 → $48 |
| 2026-09-01 | Mizuho | Target lowered | Outperform | $53 → $45 |
| 2026-09-01 | UBS | Initiated | Buy | $52 |
| 2026-08-18 | HC Wainwright & Co. | Reiterated | Buy | $50 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-11-18) | 5Y (from 2021-11-15) |
|---|---|---|
| Total return | -37.3% | -18.5% |
| S&P 500 (SPY) | +12.2% | +67.0% |
| Per year | -37.4% | -4.0% |
| Volatility (annualized) | 60.2% | 58.9% |
| Max drawdown | -49.3% (Nov 2025→Nov 2026) | -69.8% (Nov 2021→Oct 2023) |

## Dividends
ASMB paid no cash dividend in the last five years.

## Short interest
3,032,675 shares sold short, 19.82% of the float, as of Oct 30, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 30, 2026): 2,822,392 shares (+7.5%). Days to cover: 13.6 (short shares ÷ average daily volume).

## Peers (Biotechnology)
KOD (Kodiak Sciences Inc) USD 96.8 -3.90% · BLTE (Belite Bio, Inc) USD 157.72 -2.98% · ORKA (Oruka Therapeutics, Inc.) USD 96.32 -2.94% · IBRX (ImmunityBio, Inc.) USD 6.25 -0.21% · IMVT (Immunovant, Inc.) USD 33.21 -0.21% · TWST (Twist Bioscience Corporation) USD 112 +6.63%

## More
Full page: https://nexqual.com/ASMB · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Supply chain and relationships (SEC annual reports)

Named in ASMB's own 10-K filed 2026-03-19 (https://www.sec.gov/Archives/edgar/data/1426800/000119312526115992/asmb-20251231.htm):

| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | GILEAD SCIENCES, INC. (GILD) | "our ability to realize the potential benefits of our collaboration with Gilead Sciences, Inc. (Gilead), including all financial aspects of the collaboration and equity investments;" |
| Partner | Arbutus Biopharma Corp (ABUS) | "Reflects net amounts refundable to us after final reconciliation of costs for the clinical trial conducted pursuant to the Clinical Trial Collaboration Agreement with Arbutus Biopharma Corporation, which was terminated i…" |

## Company outlook (8-K filed 2026-11-12)

- "Profit-Share option for the HSV helicase primase inhibitor program – – Received first $75 million collaboration extension fee from Gilead; cash runway projected into 2029 – SOUTH SAN FRANCISCO, Calif. – November 12, 2026 – Assembly Biosciences, Inc."

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-12-31) | $1.29 | $1.37 | -5.8% | $42.8M | 3 |
| Next quarter (ends 2027-03-31) | $-0.25 | $0.02 | −$0.27 | $10.6M | 1 |
| Current fiscal year (ends 2026-12-31) | $-0.55 | $0.42 | −$0.97 | $56.6M | 2 |
| Next fiscal year (ends 2027-12-31) | $-2.72 | $-1.89 | −$0.83 | $33.3M | 4 |

## Earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| — | Quarter ended Sep 30, 2026 | −$0.93 | −$0.49 | Miss −89.8% | — |
| — | Quarter ended Jun 30, 2026 | −$0.20 | −$0.67 | Beat +70.1% | — |
| — | Quarter ended Mar 31, 2026 | −$0.54 | −$0.64 | Beat +15.6% | — |
| — | Quarter ended Dec 31, 2025 | $2.48 | −$0.85 | Beat +$3.33 | — |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

## Recent SEC filings (last 120 days)
| Filed | Form | What it says | Filing |
|---|---|---|---|
| 2026-11-16 | Schedule 13G/A | JANUS HENDERSON GROUP Ltd.: 3.3% of shares, passive 5%+ holder (amended) | https://www.sec.gov/Archives/edgar/data/1426800/000127417326000264/0001274173-26-000264-index.htm |
| 2026-11-12 | 10-Q | Quarterly report · period ended Sep 30, 2026 | https://www.sec.gov/Archives/edgar/data/1426800/000119312526458441/0001193125-26-458441-index.htm |
| 2026-11-12 | 8-K | Quarterly results | https://www.sec.gov/Archives/edgar/data/1426800/000119312526458314/0001193125-26-458314-index.htm |
| 2026-08-14 | Schedule 13G/A | Paradigm BioCapital Advisors LP, Paradigm BioCapital Advisors GP LLC: 7.8% of shares, passive 5%+ holder (amended) | https://www.sec.gov/Archives/edgar/data/1426800/000110465926097209/0001104659-26-097209-index.htm |
| 2026-08-14 | 8-K/A | Quarterly results | https://www.sec.gov/Archives/edgar/data/1426800/000119312526352193/0001193125-26-352193-index.htm |
| 2026-08-13 | 10-Q | Quarterly report · period ended Jun 30, 2026 | https://www.sec.gov/Archives/edgar/data/1426800/000119312526349236/0001193125-26-349236-index.htm |
| 2026-08-13 | 8-K | Completed an acquisition or sale of assets | https://www.sec.gov/Archives/edgar/data/1426800/000119312526349198/0001193125-26-349198-index.htm |
| 2026-08-13 | Schedule 13G/A | JANUS HENDERSON GROUP Ltd.: 6.9% of shares, passive 5%+ holder (amended) | https://www.sec.gov/Archives/edgar/data/1426800/000127417326000208/0001274173-26-000208-index.htm |
| 2026-08-04 | Schedule 13G/A | Farallon Capital Management, L.L.C., Farallon Capital Partners, L.P.: 8.1% of shares, passive 5%+ holder (amended) | https://www.sec.gov/Archives/edgar/data/1426800/000090883426000380/0000908834-26-000380-index.htm |
Source: SEC EDGAR. Quotes are the opening words of each item as filed.
